RxSight, Inc. (NASDAQ:RXST) CFO Shelley B. Thunen Sells 10,000 Shares

RxSight, Inc. (NASDAQ:RXST) CFO Shelley B. Thunen sold 10,000 shares of the business’s stock in a transaction that occurred on Monday, July 1st. The shares were sold at an average price of $58.61, for a total value of $586,100.00. Following the sale, the chief financial officer now owns 13,938 shares of the company’s stock, valued at approximately $816,906.18. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link.

RxSight Price Performance

RxSight stock opened at $56.99 on Friday. RxSight, Inc. has a 52 week low of $20.66 and a 52 week high of $66.54. The company’s 50 day moving average price is $58.74 and its two-hundred day moving average price is $52.29.

RxSight (NASDAQ:RXST) last issued its quarterly earnings results on Monday, May 6th. The company reported ($0.25) EPS for the quarter, missing analysts’ consensus estimates of ($0.17) by ($0.08). RxSight had a negative return on equity of 27.68% and a negative net margin of 44.01%. The business had revenue of $29.51 million for the quarter, compared to the consensus estimate of $27.56 million. During the same quarter last year, the business posted ($0.42) earnings per share. The business’s revenue was up 68.7% compared to the same quarter last year. On average, analysts forecast that RxSight, Inc. will post -0.77 EPS for the current fiscal year.

Hedge Funds Weigh In On RxSight

Hedge funds and other institutional investors have recently made changes to their positions in the stock. Charles Schwab Investment Management Inc. raised its position in RxSight by 157.1% in the third quarter. Charles Schwab Investment Management Inc. now owns 182,334 shares of the company’s stock worth $5,085,000 after acquiring an additional 111,403 shares during the period. HighTower Advisors LLC lifted its stake in RxSight by 7.3% in the third quarter. HighTower Advisors LLC now owns 13,256 shares of the company’s stock valued at $369,000 after purchasing an additional 899 shares during the last quarter. Trexquant Investment LP grew its holdings in RxSight by 82.9% during the third quarter. Trexquant Investment LP now owns 47,230 shares of the company’s stock valued at $1,317,000 after purchasing an additional 21,401 shares during the period. Vanguard Group Inc. increased its position in RxSight by 21.6% in the third quarter. Vanguard Group Inc. now owns 1,433,953 shares of the company’s stock worth $39,993,000 after buying an additional 255,150 shares during the last quarter. Finally, Grey Street Capital LLC bought a new stake in shares of RxSight in the fourth quarter valued at $765,000. 78.78% of the stock is owned by hedge funds and other institutional investors.

Wall Street Analysts Forecast Growth

RXST has been the subject of a number of recent research reports. BTIG Research boosted their price target on shares of RxSight from $61.00 to $72.00 and gave the company a “buy” rating in a research note on Tuesday, May 7th. Needham & Company LLC boosted their target price on shares of RxSight from $64.00 to $75.00 and gave the stock a “buy” rating in a research report on Tuesday, May 7th. Stifel Nicolaus raised their price target on shares of RxSight from $64.00 to $68.00 and gave the company a “buy” rating in a research report on Monday, May 6th. Wells Fargo & Company boosted their price objective on RxSight from $61.00 to $68.00 and gave the stock an “overweight” rating in a report on Tuesday, May 7th. Finally, Oppenheimer raised their target price on RxSight from $61.00 to $72.00 and gave the company an “outperform” rating in a report on Tuesday, May 7th. Seven research analysts have rated the stock with a buy rating, According to data from MarketBeat, RxSight currently has an average rating of “Buy” and an average price target of $60.63.

RxSight Company Profile

RxSight, Inc, a commercial-stage medical device company, engages in the research and development, manufacture, and sale of light adjustable intraocular lenses (LAL) used in cataract surgery in the United States and internationally. It offers RxSight system that enables doctors to customize and enhance the visual acuity for patients after cataract surgery.